IGHE and urticaria: In addition, UB-221 in a phase I single-dose clinical trial involving patients with CSU (ClinicalTrials.gov NCT03632291)has demonstrated durable disease symptom relief (reduction in weekly urticaria activity score, UAS7) that associates with a rapid reduction in serum free-IgE level.